Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems.

Whittle MC, Hingorani SR.

Cancer J. 2017 Nov/Dec;23(6):326-332. doi: 10.1097/PPO.0000000000000289.

PMID:
29189328
2.

Runx3 and Cell Fate Decisions in Pancreas Cancer.

Whittle MC, Hingorani SR.

Adv Exp Med Biol. 2017;962:333-352. doi: 10.1007/978-981-10-3233-2_21. Review.

PMID:
28299667
3.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

4.

Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.

Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA.

Clin Cancer Res. 2017 Mar 15;23(6):1607-1620. doi: 10.1158/1078-0432.CCR-15-1615. Epub 2016 Sep 16.

5.

RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma.

Whittle MC, Hingorani SR.

Mol Cell Oncol. 2015 Jul 29;3(2):e1076588. doi: 10.1080/23723556.2015.1076588. eCollection 2016 Mar.

6.

Disconnect between EMT and metastasis in pancreas cancer.

Whittle MC, Hingorani SR.

Oncotarget. 2015 Oct 13;6(31):30445-6. doi: 10.18632/oncotarget.5720. No abstract available.

7.

RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.

Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR.

Cell. 2015 Jun 4;161(6):1345-60. doi: 10.1016/j.cell.2015.04.048. Epub 2015 May 21.

8.

Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM.

PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013.

9.

The dynamic nature of the kinome.

Graves LM, Duncan JS, Whittle MC, Johnson GL.

Biochem J. 2013 Feb 15;450(1):1-8. doi: 10.1042/BJ20121456. Review.

10.

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE.

Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7.

11.

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL.

Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053.

12.

Defining the expressed breast cancer kinome.

Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS 3rd, Graves LM, Gomez SM, Johnson GL.

Cell Res. 2012 Apr;22(4):620-3. doi: 10.1038/cr.2012.25. Epub 2012 Feb 7. No abstract available.

Supplemental Content

Loading ...
Support Center